<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993381</url>
  </required_header>
  <id_info>
    <org_study_id>CINV_CUKorea</org_study_id>
    <nct_id>NCT01993381</nct_id>
  </id_info>
  <brief_title>Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting</brief_title>
  <official_title>Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting(CINV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most common toxicity of chemotherapy is nausea and vomiting, and appropriate management&#xD;
      of these toxicities can help patients improve tolerance for chemotherapy. Anti-emetics&#xD;
      including dopamine antagonist, serotonin antagonist, and substance P antagonist administered&#xD;
      to patients according to emetogenic risk of chemotherapeutic drugs. However, patients don't&#xD;
      always experience same nausea and vomiting for the same drugs. Therefore, it is important to&#xD;
      determine the biomarker to predict chemotherapy-induced nausea and vomiting. Some biomarkers&#xD;
      studies were done during the chemotherapy. However it is not definite evidence of relations&#xD;
      between biomarkers and chemotherapy. We will hope to find any predictive biomarker of CINV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Primary Objective To evaluate the role of some predictive biomarkers for&#xD;
           chemotherapy-induced nausea and vomiting&#xD;
&#xD;
        2. Secondary Objective To evaluate the clinical characteristics related to&#xD;
           chemotherapy-induced nausea and vomiting in Korean patients&#xD;
&#xD;
        3. Study design&#xD;
&#xD;
           Chemotherapy Day Day1 Day3 Day15&#xD;
&#xD;
           Chemotherapy 1st cycle FOLFOX/ FOLFIRI 2nd cycle FOLFOX/ FOLFIRI Blood Sampling 1st&#xD;
           sampling (8 a.m.) 2nd sampling (8 a.m.) 3rd sampling (8 a.m.) Evaluation of nausea and&#xD;
           vomiting Patient's Diary (Day 1-4)&#xD;
&#xD;
        4. Evaluation of chemotherapy-induced nausea and vomiting&#xD;
&#xD;
             -  Patient's Diary consisting of the following three elements:&#xD;
&#xD;
                  1. NCI-CTCAE (National cancer institute-common toxicity criteria adverse event)&#xD;
                     version 4.0&#xD;
&#xD;
                  2. 100mm Visual Analog Scale (VAS)&#xD;
&#xD;
                  3. Functional living index- emesis&#xD;
&#xD;
             -  Patients should write 'Patient's Diary' from chemotherapy day 1 to chemotherapy day&#xD;
                4.&#xD;
&#xD;
        5. Evaluation of the serum levels of Biomarkers (substance P et. al.) 1) Blood sampling&#xD;
&#xD;
             -  Sample 1: 1st cycle, chemotherapy starting day 1, fasting 8 a.m.&#xD;
&#xD;
             -  Sample 2: 1st cycle, chemotherapy day 3, fasting 8 a.m.&#xD;
&#xD;
             -  Sample 3: 2nd cycle, chemotherapy starting day 1 (day 15 after 1st cycle&#xD;
                chemotherapy), fasting 8 a.m.&#xD;
&#xD;
                2) ELISA test for biomarkers (Sample 1,2,3)&#xD;
&#xD;
      5. Visiting Schedule&#xD;
&#xD;
      Screening Chemotherapy Time of Visit D-3 to -1 1st day of 1st cycle (Day 1) 3rd day of 1st&#xD;
      cycle (Day 3) 4th day of 1st cycle (Day4) 1st day of 2nd cycle (Day 15) Inclusion/exclusion&#xD;
      criteria x Informed consent x Distribution of patient's diary x Blood sampling x x x Return&#xD;
      of patient's diary x&#xD;
&#xD;
      6. Statistical methods and data analysis Continuous variables, including serum levels of&#xD;
      biomarkers, are expressed as median, minimum, and maximum values. Comparisons of continuous&#xD;
      variables are made using the Mann-Whitney U test and the Kruskal-Wallis test. The chi-square&#xD;
      test is used for comparisons of categorical variables.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the role of some predictive biomarkers for chemotherapy-induced nausea and vomiting</measure>
    <time_frame>2 weeks after chemotherapy</time_frame>
    <description>Chemotherapy Day Day1 Day3 Day15&#xD;
Chemotherapy&#xD;
st cycle FOLFOX/ FOLFIRI&#xD;
nd cycle FOLFOX/ FOLFIRI Blood Sampling 1st sampling (8 a.m.) 2nd sampling (8 a.m.) 3rd sampling (8 a.m.) Evaluation of nausea and vomiting Patient's Diary (Day 1-4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the clinical characteristics related to chemotherapy-induced nausea and vomiting in Korean patients</measure>
    <time_frame>2 weeks after chemotherapy</time_frame>
    <description>Patient's Diary consisting of the following three elements:&#xD;
NCI-CTCAE (National cancer institute-common toxicity criteria adverse event) version 4.0&#xD;
100mm Visual Analog Scale (VAS)&#xD;
Functional living index- emesis&#xD;
Patients should write 'Patient's Diary' from chemotherapy day 1 to chemotherapy day 4.&#xD;
Evaluate about clinical history of patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>CINV of FOLFOX, FOLFIRI</arm_group_label>
    <description>moderate emetogenic chemotherapy</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sampling&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled to receive the first line, first cycle FOLFOX (5-FU, Oxaliplatin,&#xD;
        Leucovorin) or FOLFIRI (5-FU, Irinotecan, Leucovorin) chemotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
          -  Histologically proven solid organ cancer&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance status 0-2&#xD;
&#xD;
          -  More than 3 months for life expectancy&#xD;
&#xD;
          -  Patients scheduled to receive the first line, first cycle FOLFOX (5-FU, Oxaliplatin,&#xD;
             Leucovorin) or FOLFIRI (5-FU, Irinotecan, Leucovorin) chemotherapy&#xD;
&#xD;
          -  Patients must sign an informed consent indicating that they are aware of the&#xD;
             investigational nature of the study in keeping with the policy of the hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have nausea and vomiting caused by other reasons such as CNS metastases&#xD;
             or gastrointestinal obstruction&#xD;
&#xD;
          -  Patients who were exposed previously to any chemotherapy except adjuvant FL (5-FU and&#xD;
             leucovorin)&#xD;
&#xD;
          -  Patients who take anti-emetic drugs or dopamine antagonist within 72 hours prior to&#xD;
             administration of chemotherapy&#xD;
&#xD;
          -  Patients who take other drugs that may affect serum level of biomarkers (ex. steroid,&#xD;
             megesterol, hormone replacement therapy, parenteral nutrition)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byoungyong Shim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of medical oncology, The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byoungyong Shim, Ph.D., M.D</last_name>
      <phone>82-31-249-8457</phone>
    </contact>
    <investigator>
      <last_name>Byoungyong Shim, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Byoungyong Shim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>chemotherapy-induced nausea and vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

